Moreover, only the combination of riociguat with 5Z-7-oxozeaenol was able to normalize the metabolic dysregulation found in the RV rats with PAH suggesting that the inhibition of TAK1 might represent a cardioprotective target for the treatment of RV failure associated to PAH. This evidence concerns the gene MAP3K7 and pulmonary arterial hypertension.